Circadian Rhythm Deregulation in Patients With CAPS

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6+
SponsorHospices Civils de Lyon

About this trial

Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within each cell. At the molecular level, the circadian clock is based on a complex system of cell-autonomous transcription loops. These exert positive and negative feedback on themselves, generating cyclic transcriptional activity.

* In the main loop, the BMAL1 transcription factor links with CLOCK or NPAS2 ( (Neuronal PAS Domain Protein 2) to activate transcription of per1,2 and 3 and cryptochrome (cry1 and cry2), which in turn repress BMAL1/CLOCK1 transcriptional activity.. The BMAL1/CLOCK complex also activates transcription of numerous target genes (per and cry, Rev-erb, etc.).. * other secondary loops refine the function of the first.

Recent studies suggest that many aspects of innate immunity are controlled by circadian rhythm through inhibition of NLRP3 inflammasome activation. Nevertheless, the regulation of the NLRP3 inflammasome by the circadian clock has yet to be elucidated. Inflammasomes are molecular platforms that control caspase-1 activation and consequently the maturation of precursors of (interleukine) IL-1β, pro-IL-18, a pro-inflammatory cytokine. Since its discovery, its functions have been widely characterized as part of the innate immune response as a sensor of pathogens and danger signals (extracellular ATP (Adenosine triphosphate), atmospheric pollutants). NLRP3 (nucleotide-binding domain LRR (leucin-rich repeat ) and pyrin-containing receptor 3) has been described for its genetic association with dominant monogenic hereditary syndromes characterized by recurrent systemic inflammatory episodes in the absence of any infection or autoimmune disease, known as CAPS (cryopyrin-associated periodic syndrome) or cryopyrinopathies which is a continuum of diseases ranging from a moderate to the most severe form of the syndrome: familial cold urticaria syndrome, Muckle-Wells syndrome (MWS), and CINCA/NOMID syndrome.

Interestingly, patients with Muckle-Wells syndrome show a circadian pattern of symptoms, with a recurrent, predominantly vesperal fever peak lasting a few hours, and extreme fatigue on a daily basis. However, a molecular link between the circadian clock and CAPS pathology remains to be determined.

The aim of this protocol is to identify circadian rhythm dysregulation in patients with CAPS confirmed by genetic analysis of NLRP3, to demonstrate a link between circadian clock and CAPS syndrome, and to identify circadian clock regulatory pathways.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients aged 6 and over

Participant with CAPS confirmed by NLRP3 genetic analysis

Weight greater than or equal to 25 Kg

Parents/guardians who have been informed of the study and have signed a consent form.

Disqualifiers

Patients with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin).

Patients with sleep apnea syndrome

Patients working regular night shifts or alternating day and night shifts

Pregnant or breast-feeding women

Trial design

Design model

Parallel

Treatments tested in this trial

  • Genetic analysis of NLRP3

    Genetic

    Blood test for genetic analysis of NLRP3

  • Circadian rhythm measurement

    Device

    Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm

  • Saliva sampling

    Biological/Vaccine

    Saliva sampling for salivary melatonin determination

  • Questionnaire

    Other intervention

    Questionnaire to determine chronotype

  • AIDAI score

    Other intervention

    Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX

  • Blood sampling

    Biological/Vaccine

    1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18. 2. Molecular characterization of circadian clock signaling pathways

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: Patients with cryopyrin-associated periodic syndrome (CAPS)Active comparator 6 interventions
Group B: Control groupPlacebo comparator 5 interventions

Trial outcomes

Primary outcomes

1

Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,

Concentration of the peak secretion of melatonin in both arms

Time frame
6 months after inclusion
2

Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,

Concentration of the peak secretion of melatonin in both arms

Time frame
12 months after inclusion
3

Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,

time of the peak secretion of melatonin in both arms

Time frame
6 months after inclusion
4

Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,

time of the peak secretion of melatonin in both arms

Time frame
12 months after inclusion

Secondary outcomes

1

Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.

Determination of circadian rhythms : amplitude in both arms

Time frame
6 th month
2

Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.

Determination of circadian rhythms : period in both arms

Time frame
6 th month
3

Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.

Determination of circadian rhythms : phase in both arms

Time frame
6 th month
4

Chronotype determination

Number of patients in each chronotype for the 2 arms based on the specific questionnaire in both arm

Time frame
6 th month

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.